Recordati and Partners to Present New Evidence and Guidance in Rare Hematologic Diseases at American Society of Hematology (ASH) Annual Meeting and Exposition
Updated global consensus guidelines for cold agglutinin disease (CAD), alongside post-hoc Phase 3 analysis and real-world data, supplement evidence of sutimlimab long-term safety and efficacy in CAD Research findings and the first globally validated symptom burden tool for idiopathic...
Covered in this story
Call it yourself
No calls on $ASH yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ashland →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.